Busulfan influences engraftment and toxicities during hematopoietic stem cell transplantation (HSCT). We report our single-institution experience of targeted busulfan therapy for myeloablative, matched sibling donor (MSD) HSCT for sickle cell disease (SCD) and assess the relationships of busulfan levels to engraftment and toxicities. Twenty-seven patients with SCD underwent MSD HSCT from 1993 to 2007, 25 with busulfan measurements. The conditioning regimen was busulfan (initial dose 0.875 mg/kg for 16 doses), CY and antithymocyte globulin. Busulfan area under curve (AUC) was determined with the first dose, and dose adjustments were made to target the desired AUC range. Median AUC was 963 lmol min/L (range 780-1305 lmol min/L). Engraftment occurred in all cases: 21 (84%) full donor chimerism (495% donor cells), 4 (16%) partial donor chimerism. Hepatic veno-occlusive disease (VOD) occurred in 8 (32%) patients. Lower AUC was seen with partial donor chimerism (862±73 lmol min/L) versus full donor chimerism (AUC 1018 ± 122 lmol min/L) (P ¼ 0.022). VOD was not associated with busulfan AUC (P ¼ 0.153). Of 25 patients, 24 survived with median follow-up of 4.9 years. Our experience shows that targeting busulfan AUC above the range used in previous multicenter trials appears safe and may contribute to sustained engraftment in SCD.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is curative therapy for sickle cell disease (SCD). Widespread use of HSCT for the majority of patients with SCD has been limited by the availability of suitable donors as well as the risks of morbidity and graft failure. Nearly all myeloablative HSCT conditioning regimens for SCD incorporate the alkylating agent busulfan. Total systemic exposure to busulfan has been shown to be a major determinant of the degree of myeloablation 1 and successful engraftment in HSCT for thalassemia and other diseases; 2,3 however, higher busulfan dosing is limited by acute toxicities, including hepatic veno-occlusive disease (VOD), interstitial pneumonitis and seizures. [4] [5] [6] These considerations are relevant to HSCT for children with SCD, given that their risk for graft rejection is approximately 10% 7 and that preexisting cerebrovascular disease and transfusion-related hepatotoxicity in these patients may predispose to further organ toxicities that are associated with busulfan during HSCT.
Pharmacokinetic (PK) monitoring of busulfan is an accepted practice that allows clinicians to monitor and adjust systemic busulfan levels to achieve a target therapeutic window. In general for pediatric patients receiving HSCT, the overall busulfan area under curve (AUC) exposure is targeted within a broad therapeutic range of 900-1500 mmol min/L; [8] [9] [10] [11] [12] however, no formal studies have evaluated this AUC range in pediatric patients with SCD. The collaborative Multicenter Study of HSCT for SCD recommended a targeted busulfan steady-state concentration (Css) of 400-600 ng/mL (equivalent to AUC 585-877 mmol min/L). 13 Patients on this trial had a 9% rate of graft rejection and a 15% rate of partial donor chimerism. 7, 13, 14 Previous published experiences of myeloablative HSCT for SCD using busulfan have not reported the results of busulfan PK levels and dose adjustments. In our center's experience of HSCT for SCD, the busulfan PK target has varied broadly among patients, providing us with the opportunity to assess the safety of a range of busulfan drug levels and the potential impact of drug levels on engraftment and transplant-related morbidity. In this study, we report our single institution's experience of targeted busulfan PK for pediatric patients with severe SCD undergoing HLA-matched sibling donor (MSD) HSCT and compare these PK levels to the range reported in other studies of HSCT for SCD.
Subjects and methods

Subject eligibility
A retrospective review of busulfan PK and outcomes of patients who received MSD HSCT with BM allografts at Children's Healthcare of Atlanta from December 1993 to August 2007 was conducted with institutional review board approval. Primary outcomes of interest were sustained donor engraftment and chimerism and the occurrence of busulfan-related toxicities, defined as hepatic VOD, interstitial pneumonitis and seizures within 24 h of busulfan dosing. Patients were considered for MSD HSCT if they met one or more criteria of disease severity as previously described by Walters et al., 15 which included a history of cerebrovascular accident or abnormal cerebral magnetic resonance imaging scan, recurrent acute chest syndrome, recurrent vaso-occlusive pain, osteonecrosis of multiple joints and RBC alloimmunization with X2 antibodies in a patient receiving chronic transfusion therapy.
Conditioning regimen and graft
Patients received busulfan at an initial dose of 0.875 mg/kg every 6 h for a total of 16 doses on days À9 to À6 (total dose 14 mg/kg), CY 50 mg/kg once daily on days À5 to À2 (total dose 200 mg/kg) and antithymocyte globulin 30 mg/kg daily on days À4 to À2 (total dose 90 mg/kg PK analysis PK analysis of busulfan was performed with the first dose, and based on the first dose AUC, dose adjustments were made as needed to target the desired AUC range. Plasma busulfan concentrations were determined by gas chromatography with electron capture detector before the dose and at nine time points after orally administered doses (15, 30, 60, 90, 120, 180, 240 , 300 and 360 min) or at four time points after completion of i.v. infusion (15, 60, 120 and 240 min). The busulfan AUC and elimination half-life were calculated using a combination of linear and logarithmic trapezoidal rules as described by Grochow. 16 Area during the infusion was calculated using the linear rule, and the post infusion areas were calculated using the logarithmic rule. For first dose levels, the area from the last concentration to infinity was calculated using the elimination rate constant determined by regression of the log-transformed levels of the elimination phase. When dose adjustments were made due to a first dose AUC outside of the target range, repeat PK measurements were made with the new dose at the discretion of the treating physician. The overall busulfan AUC reported is the weighted average of the AUC value of the starting dose (based on the measured AUC) and the targeted AUC values of subsequent doses. During the study period, the desired targeted AUC range varied: from 1996 to July 1999, busulfan AUC was targeted to 585-877 mmol min/L (Css 400-600 ng/mL), as per the Multicenter Study for HSCT in SCD (n ¼ 5 patients); from August 1999 to April 2004 the targeted busulfan AUC was broadened to o1500 mmol min/L (with no lower limit specified) (n ¼ 10 patients); from May 2004 onward, target AUC range was 900-1100 mmol min/L (n ¼ 10 patients).
Evaluation of clinical data Diagnosis of VOD was made by the patient's medical treatment team and was confirmed for this study by verifying at least two of three criteria defined by McDonald et al. 17, 18 : hyperbilirubinemia (total serum bilirubin 42 mg per 100 mL), tender hepatomegaly and weight gain 42% of baseline body weight due to fluid accumulation within 20 days of transplantation. Severe VOD was defined as persistent symptoms beyond day 100 or death before day 100 with VOD. Duration of chronic transfusion therapy and quantitative liver iron to assess for iron overload before HSCT were recorded to assess the relationship of pre-transplant hepatotoxicity to the occurrence of VOD. Donor marrow engraftment was assessed from whole blood by variable number tandem repeat DNA analysis for same sex donors and by FISH analysis of X and Y chromosomes for opposite sex donors at days 30, 100, 1 year and then annually. Donor chimerism status determined at 12 months after BMT was defined as full donor for 495% donor cells, high partial donor for 50-95% donor cells, low partial donor for 5-49% donor cells and graft rejection for o5% donor cells.
Statistical analysis
Primary outcome variables were sustained donor chimerism status and the occurrence of VOD and other busulfanrelated toxicities. Comparisons of each outcome to busulfan AUC, cumulative busulfan dose, age, weight and stem cell dose were made by Student's t-test or Wilcoxon rank-sum test as appropriate; comparisons of VOD occurrence to pre-HSCT serum ferritin, quantitative liver iron and chronic transfusion therapy were made by w 2 -test comparison or Fisher's exact test as appropriate. Pearson correlation coefficient (r) was calculated to assess the linear relationship of busulfan AUC to age. Disease-free survival was defined as survival with o50% hemoglobin S and the absence of vasoocclusive complications. Statistical analysis was performed using SAS version 9.2 (SAS Institute, Cary, NC, USA) statistical software package.
Results
Patient characteristics
Between December 1993 and August 2007, 27 patients (12 female, 15 male) with hemoglobin SS SCD received myeloablative MSD HSCT with BM allografts at Children's Healthcare of Atlanta. The first two patients transplanted in this time period survive with full donor chimerism; however, they did not have busulfan PK monitoring, and thus are excluded from this analysis. Characteristics of 25 evaluable patients for whom busulfan PK monitoring was performed are summarized in Table 1 . The median age at time of BMT was 8.6 years (range 3.3-17.4 years), with 5 (20%) children below the age of 6 years. Seventeen patients (68%) had cerebrovascular disease before HSCT. Eleven (44%) had received chronic transfusion therapy for more than 1 year, of whom the majority had pre-HSCT iron overload as shown by elevated serum ferritin and/or liver iron quantification.
HSCT outcomes
The overall and disease-free survival rate was 96%, with a median survivor follow-up time of 4.9 years (range 1.0-10.0 years), and high functional performance status among all survivors. All transplants resulted in sustained engraftment of donor cells with no late graft rejection. Twenty-one transplants (84%) resulted in full donor chimerism, whereas four transplants (16%) resulted in sustained high partial donor mixed chimerism. The percentage of donor engraftment ranged from 62 to 100%. Chimerism status was followed for a median of 3.4 years (range 0.3-10.0 years); one patient who had full engraftment for 5.9 years after HSCT had a decline to partial chimerism (91% donor) at 7.3 years. Nine (36%) patients had toxicities that previously have been associated with busulfan, including eight patients with VOD (no severe VOD) and one patient with interstitial pneumonitis concurrent with parainfluenza respiratory infection. No seizures occurred during or up to 24 h after busulfan administration. Four (16%) patients had seizures after transplantation, two with intracranial hemorrhage. Three (12%) patients developed grade I-II acute GVHD. One death occurred due to grade IV GVHD (gastrointestinal stage 4) on day 109 of transplant; this patient had full donor engraftment with no evidence of busulfan-related toxicities.
Busulfan administration and PK Busulfan was administered orally in 17 patients and intravenously in 8 patients. Comparison of busulfan dosing, PK and toxicities in patients receiving oral versus i.v. busulfan is shown in Table 2 . Three patients had delayed oral absorption of the first dose of busulfan, thus the first dose busulfan levels could not be evaluated reliably. Because the first dose AUC appeared to be higher than intended in these three patients, the initial doses were decreased, and busulfan measurements were repeated for the decreased dose. The AUC for the starting dose was re-estimated based on the AUC measurements for the reduced dose, to calculate the overall busulfan AUC more precisely.
The distributions of the first dose AUC and overall busulfan AUC for the entire study group (both oral and i.v. administration) are shown in Figure 1 . The median AUC for the first dose was 968 mmol min/L (range 595-1379 mmol min/L); after dose adjustments the median overall AUC was 963 mmol min/L (range 780-1305 mmol min/L). No patient had an individual dose AUC X1500 mmol min/L. First dose AUC tended to be lower with younger age (correlation of AUC with age: r ¼ 0.471, P ¼ 0.0175), however, with dose adjustment overall AUC did not correlate significantly with age (r ¼ 0.376, P ¼ 0.064).
Seventeen (68%) patients had at least one dose adjustment. Although the decision to adjust the dose was dependent on the desired targeted AUC range, which varied during the study period, there was no significant difference in overall AUC between patients who had zero versus one dose adjustment. The median dose increase was 16% above the original dose (range 10-76%), whereas the median dose decrease was 6% below the original dose (range 4-28%). Three patients (two with oral and one with i.v. administration) required dose adjustments at two time points. VOD occurred most often among the eight patients with zero dose adjustments (63% with VOD) as compared to patients with one adjustment (21% with VOD) or two adjustments (0% with VOD) (P ¼ 0.06). The patients without dose adjustments all received oral busulfan, and all but one of these patients was treated with an intended target AUC o1500 mmol min/L; thus any association between the occurrence of dose adjustment and occurrence of VOD may be confounded by target AUC, route of administration or supportive care measures of the earlier time period.
Relationship of busulfan AUC to HSCT outcomes
Characteristics and busulfan PK of patients with full and partial donor chimerism are compared in Table 4 . Patients with VOD did not have a significantly different overall busulfan AUC (1059 ± 162, range 821-1305 mmol min/L) when compared to patients without VOD (AUC 962 ± 100, range 780-1184 mmol min/L), (P ¼ 0.153) (Figure 3 ). Patients' age, weight, earlier chronic transfusion therapy and pre-HSCT hepatic hemosiderosis and fibrosis were not associated with occurrence of VOD.
Discussion
This is the first report to provide an analysis of the PK of targeted busulfan therapy in children with SCD undergoing myeloablative MSD HSCT. Our experience shows sustained donor engraftment in 100% of patients and 96% overall survival without excessive acute busulfan-related toxicities in our targeted AUC range. Previous publications have reported overall survival of 93 and 93.1% and eventfree survival of 85 and 86.1%, in the Multicenter Study of HSCT in SCD and the French transplantation experience, respectively. 14, 19 The Multicenter Study treatment regimen measured busulfan PK to target the AUC between 585-877 mmol min/L (Css 400-600 ng/mL), whereas the French treatment regimen used a higher busulfan dose (not less than 16 mg/kg); however, neither study provided analysis of busulfan PK measurements for comparison to our group.
Our experience is notable for the absence of graft rejection in any patients and showed that partial donor engraftment was associated with significantly lower busulfan levels as compared to patients with long-term full donor chimerism. Factors that contribute to favorable engraftment outcomes are numerous. Because no graft rejection occurred in our cohort of 25 patients, definitive conclusions regarding the impact of busulfan levels on engraftment outcome cannot be determined. Stable mixed chimerism is an acceptable aim for HSCT for SCD and other nonmalignant conditions, and is sufficient to prevent further SCD complications; 7, [20] [21] [22] however, comparison of characteristics between patients with full versus high partial donor chimerism is valuable in that it may lend insight into variables that contribute to successful engraftment in patients with SCD.
In multivariate analysis, the only variable to show a positive association with full versus partial donor chimerism was the overall busulfan AUC level. In the Multicenter Table 2 Comparison of busulfan dosing, pharmacokinetics and toxicities in patients who received oral versus intravenous busulfan Study, younger age and iron chelation therapy were associated with the occurrence of partial mixed chimerism and graft rejection, respectively; 7 however, these associations were not observed in our cohort, despite having similar proportions of young patients and patients with earlier chronic transfusions and chelation therapy. Surprisingly, CD34 þ cell dose was significantly higher among those with partial donor chimerism. Although no causality within this association can be determined, this finding does suggest that the significant association of partial donor chimerism with lower busulfan AUC was not confounded by low CD34 þ cell doses.
The association of total systemic busulfan levels with sustained donor chimerism outcome is a novel finding for patients with SCD, although it is not entirely surprising. Several studies have shown that lower busulfan AUC predicts graft rejection in pediatric 8, 12 and adult patients 2 with a variety of HSCT indications and specifically in thalassemia major, a disorder that shares a rate of HSCT graft failure similar to SCD. 3, 23, 24 A minimum threshold for measured busulfan levels appears to be necessary for successful engraftment in patients with hemoglobinopathy. 2, 25 Higher busulfan AUC has been associated with increased toxicities such as VOD and mortality, particularly in adult patients with AUC 41500 mmol min/L. 2, 5, 25, 26 Although it has been shown that busulfan levels in children have not been associated with occurrence of VOD, possibly due to faster busulfan clearance and greater volume of drug distribution, 26, 27 concerns regarding busulfan-related toxicities among pediatric patients with SCD may still exist due to the high prevalence of hepatic, cerebrovascular and pulmonary disease in this population. 19, [28] [29] [30] The incidence of VOD during HSCT for pediatric patients with SCD has not been reported previously. In this analysis nearly one third of patients experienced VOD. A trend toward a higher rate of VOD was seen with oral busulfan as opposed to i.v. administration, which is consistent with several past studies in non-SCD patients; 12, 31, 32 this trend, however, was not statistically significant in our cohort. Within our targeted range of AUC, cumulative busulfan exposure was not significantly associated with hepatic VOD or other acute toxicities. Thus, our current practice of targeting the busulfan AUC to a goal range of 900-1100 mmol min/L (above the previous recommendation of 585-877 mmol min/L) appears to be safe in terms of acute toxicity risk. Targeting higher busulfan AUC may be beneficial in achieving long-term full-donor chimerism; however, this benefit must be balanced against the potential long-term effects of high-dose alkylating agents, including gonadal dysfunction and pulmonary toxicity.
Although no variables were identified as clear predictors of VOD in this study, the relatively high incidence of VOD in our cohort suggests that all patients with SCD are at significant risk for VOD due to their underlying disease. The pathogenesis of VOD is multifactorial and may also be caused by damage from high-dose alkylating agents, including CY in combination with busulfan, and previous hepatic endothelial damage. 33, 34 Chronic endothelial Table 3 Comparison of patients with full versus high partial donor chimerism damage and vasculopathy are hallmarks of SCD pathophysiology 35 and could contribute to hepatic sinusoidal endothelial damage during HSCT. Interestingly, although hepatic hemosiderosis and fibrosis in patients with beta-thalassemia are known to be associated with increased HSCT mortality, 23, 24 in our cohort, these findings were not predictive of VOD or other morbidity.
This review represents the first analysis of busulfan PK monitoring and its influence on HSCT outcomes specifically in pediatric patients with SCD. Although the retrospective nature of the study and the variation in clinical management of busulfan exposure over the study period limits the ability to make definitive conclusions about optimal busulfan levels, the finding of a relationship between busulfan AUC and sustained donor chimerism highlights the importance of performing targeted busulfan PK. In future prospective trials of reduced intensity HSCT, specific focus on busulfan PK and targeted AUC will lend further insight into strategies to achieve successful long-term donor engraftment in pediatric patients with SCD. Patients' age, weight, busulfan AUC and total busulfan doses are expressed as the mean±1 standard deviation (range). Serum ferritin levels were obtained in 20 (80%) and liver biopsies were obtained in 9 (36%) patients before HSCT.
